News
London, 12 November 2008
ImmuPharma awarded grant for developing cancer drug
ImmuPharma PLC (LSE:IMM), ("ImmuPharma or the "Company") the specialist drug discovery and development company, is pleased to announce that it has been awarded €0.9m as one of the two grants it has been anticipating from French government organisations. The grants are to be used for the development of ImmuPharma's cancer drug candidate IPP-204106.
London, 21 October 2008
LupuzorTM patents allowed in US and approved in Japan, Australia - other countries expected to follow
ImmuPharma PLC (LSE:IMM), ("ImmuPharma or the "Company") the specialist drug discovery and development company, is pleased to announce that the LupuzorTM patent was approved in Japan and Australia and received notice of allowance from in the US Patent Office. LupuzorTM is ImmuPharma's lead drug compound for the potential treatment of Lupus, a chronic, life-threatening autoimmune disease.
In addition, the mechanism of action of LupuzorTM has been identified by researchers working with ImmuPharma at the Centre National de la Recherche Scientifique in Strasbourg. LupuzorTM has shown that it modulates, through a unique mechanism, a specific subset of CD4 T cells which play a critical role in the physiopathology of Lupus.
London, 17 October 2008
ImmuPharma PLC (the "Company")
Additional Listing and Total Voting Rights
Following the receipt of notices of exercise of options, application has been made to the London Stock Exchange for the admission of 132,000 new ordinary shares to trading on AIM.
London, 25 September 2008
Interim results announcement for the
six months ended 30
June 2008
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2008.
INTERIM HIGHLIGHTS
■ First patients dosed in Phase IIb trial of our lead asset for lupus, IPP-201101, during the period under review with subsequent ongoing progress being made and headline efficacy data expected later in the year;
■ Successfully obtained LUPUZOR™ trademark for IPP-201101, our lead asset for lupus
■ Encouraging pre-clinical data from new portfolio candidate, IPP-204106 for multiple forms of cancer
■ Raised £2.7m in a share placing from UK and Swiss institutional investors;
■ In addition to our discovery pipeline, our portfolio now
includes five drug candidates:
□ IPP-201101, LUPUZOR™ for the treatment of
lupus
□ IPP-204106, for the treatment of cancer
□ IPP-201007, for the treatment of
inflammation
□ IPP-102199, for the treatment of moderate
and severe pain
□ IPP-203101, for the treatment of MRSA and
other hospital-
acquired infections
Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said: "The first half of 2008 has been an exciting time for ImmuPharma with the addition of IPP-204106 for the treatment of cancer, the first patients being dosed with LUPUZOR™ and ongoing progress being made in a Phase IIb trial that is anticipated to report headline efficacy data later in the year, and a successful share placement raising £2.7m. The Company continues to develop its assets and discussions with potential partners."
London, 10 July 2008
ImmuPharma raises additional £1.1 million (CHF 2.2 million) to advance development programmes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has raised additional proceeds of approximately £1.1 million (£1.07 million net of expenses) or approximately CHF 2.2 million principally from institutional investors based in Switzerland through a placing of 1,876,000 new ordinary shares of 10p each in the Company at a price of 60 pence per share. This represents the final tranche of the placing announced by the Company on 2 July 2008 (the “Placing”) and is subject to the same terms and conditions, as set out in the Appendix to this announcement.
London, 2 July 2008
Long term toxicology studies confirmed the safety of LupuzorTM
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today LupuzorTM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme.
London, 2 July 2008
ImmuPharma raises £1.6 million to advance development programmes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has raised approximately £1.6 million (approximately £1.5 million net of expenses) principally from institutional investors through a placing of 2,697,034 new ordinary shares of 10p each in the Company at a price of 60 pence per share subject to the terms and conditions set out in the Appendix to this announcement (the "Placing").
London, 20 May 2008
ImmuPharma’s cancer drug candidate IPP- 204106 shows complete response to tumours in multiple human cancer cell lines
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today pre-clinical data on its new cancer drug, IPP-204106. Data on ImmuPharma’s anti-cancer nucleolin antagonist (“Nucant”) peptide programme, IPP-204106 have been obtained confirming the ability of the compounds to effectively control and stop the growth of a large panel of human cancer cell lines both "in vitro" and "in vivo". Collectively the studies comprised breast cancer, prostate cancer, melanoma, glioblastoma, leukaemia, colon cancer and pancreatic cancer cell lines.
London, 13 May 2008
Lupus drug candidate IPP-201101 obtains trademark LUPUZOR TM
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that it received approval of its trademark name LUPUZOR TM for its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark Office.
London, 8 May 2008
PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December 2007
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary results for the year ended 31 December 2007.
Key Highlights:
■
Recruitment of patients well underway with IPP-201101, drug candidate
for the treatment of Systemic Lupus Erythematosus, in pivotal Phase IIb
trial
■ Added a novel drug candidate to the pipeline, IPP-204106, for
cancer; rights obtained from Centre National de la Recherche
Scientifique (CNRS)
■
Discovery of a new lead candidate for inflammation, IPP-201007 from
internal proprietary chemical library
■
Consolidated cash balance at 31 December 2007 of approx £2.9 million.
London, 26 February 2008
First Lupus patients dosed with IPP-201101 in phase IIb study
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today announces today that the first patients have been dosed in its phase IIb trial of IPP-201101 for the treatment of Systemic Lupus Erythematosus. Assuming continued satisfactory patient recruitment with the trial, headline efficacy data are expected in the summer of 2008 as previously indicated.
London, 8 January 2008
ImmuPharma enters oncology with novel potential blockbuster drug for multiple cancer indications
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that, as part of its ongoing research collaboration with the Centre National de la Recherche Scientifique ("CNRS"), France's scientific research institution, it has taken the rights for the worldwide development and commercialization of a novel drug candidate for cancer.
The molecule, code-named IPP-204106, has a dual mechanism of action, acting both in preventing angiogenesis as well as proliferation. IPP-204106 is a nucleolin antagonist, the lead molecule in a family of pseudopeptides designed to block the activity of a protein called nucleolin. Located essentially in the nucleus of normal cells where it is protected, nucleolin is much more abundant (often 100 times more) at the surface of the cells which are proliferating as well as the surface of active endothelial cells where it can be a target for antagonist peptides.
London, 18 December 2007
Directors’ Dealing
Powe Capital increases stake in ImmuPharma to over 5%
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), announces today that Powe Capital, through its funds Modulus Europe and Tensor Europe, has increased its stake in ImmuPharma from 3.12% to 5.59% through a purchase, on 14 December 2007, of 1,800,000 existing ordinary shares of 10 pence each in the Company from the Trusts of two of ImmuPharma's founders and Directors, Richard Warr and Dimitri Dimitriou.
London, 6 December 2007
Initiation of Phase IIb trials for IPP - 201101 in patients with Lupus; Allows earlier release of efficacy data in mid 2008
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, announces today that following its discussions with the US Food and Drug Administration ("FDA"), it has obtained feedback that refines the phase II/III programme for IPP- 201101 in patients with Systemic Lupus Erythematosus. The outcome of this consultation with the regulator has been the segmenting of the development programme into separate phase IIb and phase III trials. The company had previously expected a single phase II/III trial in 240 patients over 12 months. The revised plans allow the company to have additional phase II data, which has the potential to enhance its commercial attractiveness, earlier than previously expected and continuing with a simpler phase III trial in Q3 2008, broadly in line with previous development timelines. ImmuPharma expects the first patients to be dosed into the phase IIb trials very shortly.
London, 16 November 2007
Appointment of NOMAD and corporate broker
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, is pleased to announce the appointment of Panmure Gordon & Co as its NOMAD and corporate broker with immediate effect.
London, 28 September 2007
INTERIM RESULTS ANNOUNCEMENT
For the six month ended 30 June 2007
ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and development company is pleased to announce its interim results for the six months ended 30 June 2007.
INTERIM HIGHLIGHTS
• Submitted file to the FDA for phase II / III
programme for lead drug for
Lupus
• Discovered new lead drug candidate for inflammation
• Continued development progress of other R&D assets
• Appointed two board members with pharma industry experience
• Appointed Teather & Greenwood (now Landsbanki) as nominated
adviser and broker while retaining Dawnay, Day Corporate Finance as
joint financial adviser
• Cash and cash equivalents at 30th June 2007 were £4,826,994,
compared to £6,459,918 at 31st December 2006.
London, 22 August 2007
ImmuPharma discovers new lead drug candidate for inflammation
ImmuPharma plc (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announced today that following its discovery activities on its chemical library, it has discovered a new molecular series with potential application in inflammatory/allergic conditions such as asthma and rheumatoid arthritis. These molecules, in the programme code-named IPP-201007, have utility as selective phospholipase A2 subtype inhibitors and are already patented through ImmuPharma's library broad patent.
London, 20 August 2007
AIM Rule 26
ImmuPharma plc (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, today announces that the information required by Rule 26 of the AIM Rules for Companies (February 2007) is available in the investor section of the Company's website at www.immupharma.com/AIM_Rule_26_Information.html
London, 13 August 2007
Directors' Dealing
ImmuPharma plc (LSE:IMM),("ImmuPharma" or the "Company"), received notification of a private placement of existing shares to institutions and private investors, including Quest Management, Morley, Odey Asset Management, Cheviot and Celeste. The shares were placed to satisfy demand and increase liquidity, from the holdings of two of the founding Directors.
London, 10 July 2007
ImmuPharma submits file to the FDA for
pivotal phase II/III trial in Lupus patients
ImmuPharma plc (LSE:IMM),("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announced today that it has just submitted an IND (Investigational New Drug) file to the US Food and Drug Administration (FDA) for the initiation of a pivotal phase II/III trial for its drug IPP-201101 in patients suffering from Systemic Lupus Erythematosus.
London, 13 June 2007
PRELIMINARY RESULTS
AGM Statement and Board Update
ImmuPharma plc (LSE:IMM), the
specialist pharmaceutical discovery and development company, held its
AGM earlier today and is pleased to
announce that all resolutions were passed.
Paddy Walker-Taylor, 60, currently part-time finance director, has
decided by mutual agreement with the company to resign his role as
director but remain with the company on a reduced-time basis.
London, 1 May 2007
PRELIMINARY RESULTS
for the period ended 31st December 2006
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist pharmaceutical discovery and development company is pleased
to announce its preliminary results for the period ended 31st December
2006.
Key Highlights:
• Successful completion of Phase II trial of our lead compound
IPP-201101, for the treatment of Lupus.
• Positive discussions held with FDA and plans for a Phase II/III
multicentre study in the US and Europe.
• Cash reserves strengthened with a further €7m funds raised.
London, 27 April 2007
Board Appointment
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, today announces the appointment of Ajay Agrawal (42) as a non-executive director. Dr Agrawal has almost 20 years' experience in the biotech and pharmaceutical industry worldwide.
London, 15 February 2007
Appointment of adviser
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is pleased to announce the appointment of Teather & Greenwood Limited as nominated adviser and broker. The appointment is with immediate effect.
Dawnay, Day Corporate Finance Limited continues to act for ImmuPharma plc as joint financial adviser.
London, 07 February 2007
Board Changes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announced today the following changes to its Board and a senior management appointment.
London, 21 December 2006
ImmuPharma raises €7 million to advance programmes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announced today that it has successfully raised just over €7 million (£4.71m) through the issue of new shares and an interest free unsecured Bond with warrants.
London, 30 October 2006
ImmuPharma announces further data from its IPP- 201101 phase II Lupus trial showing significant clinical improvement in patients
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, announced today further data from its phase II trial with IPP-201101 for Lupus. Patients who received IPP-201101 on only 3 occasions, 2 weeks apart, demonstrated a significant clinical improvement in their condition in addition to the decrease of their biomarkers.
London, 17 October 2006
ImmuPharma announces highly positive preliminary Phase II results for its potential blockbuster treatment for Lupus
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announced today that its potential blockbuster IPP-201101 for Lupus treatment has met its Phase II primary endpoints.
London, 2 October 2006
ImmuPharma Announces Summary of Meeting with FDA for design of development programme for IPP-201101 treatment for Lupus
- Feedback reinforces model for potential fast track approval -
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, announced today that it held a meeting with the United States Food and Drug Administration (“FDA”) on its IPP-201101 treatment for Lupus, a chronic, life-threatening autoimmune disease.
The meeting was held following the successful completion of the phase I trial of IPP-201101 and the initiation of the phase II trial, results of which are due to be announced before year-end. The purpose of the meeting was to discuss technical and scientific information and the proposed clinical protocol design for IPP-201101.
London, 26 SEPTEMBER 2006
IMMUPHARMA PLC
INTERIM RESULTS ANNOUNCEMENT
for the the three months ended 30th June 2006
ImmuPharma plc (LSE:IMM), (the "Company" or the "Group"), the specialist
pharmaceutical discovery and development Company is pleased to announce its
interim results for the three months ended 30th June 2006.
The interim figures are for three months due to the accounting reference
date of the Company year end being changed from 31st March to 31st
December, as highlighted in the full year statement issued on 1st August
2006.
London, 1 August 2006
IMMUPHARMA PLC
PRELIMINARY RESULTS
for the period ended 31 March 2006
ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and
development company is pleased to announce its preliminary results for the
period ended 31 March 2006.
Key Highlights:
• Successful placing and admission to AIM through reverse take over
in February 2006
• Received €1m in European Grant Funding from prestigious French
innovation agency in April 2006
• Successful completion of Phase I trial of our lead compound
IPP-201101, for the treatment of Lupus
• Phase II trials commenced in June 2006
London, 5 July 2006
ImmuPharma IPP- 201101 treatment for Lupus enters Phase II
- First patients dosed -
- Results expected before end of 2006 -
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announced today that its IPP-201101 treatment for Lupus, a chronic, life-threatening autoimmune disease, has entered into Phase II clinical trials. The first group of Lupus patients in the study have already been given the drug.
This European Phase II study in Lupus patients is a proof of concept, dose ranging, safety and efficacy study. The efficacy will be assessed using appropriate surrogate markers that are involved in the disease and biomarkers related to mechanism of action of IPP-201101. Results from this short duration study, expected by year end, will be of great value in preparation of pivotal Phase III studies.
London, 10 May 2006
ImmuPharma announces successful results from its phase I clinical trial with IPP-201101 for Lupus
- Phase II to start soon -
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announced today that it has successfully completed the
placebo-controlled phase I study involving 24 healthy volunteers of its
lead compound IPP-201101 for Lupus, a chronic, life-threatening autoimmune
disease.
This study, which took place in France, was the first administration in
humans for IPP-201101 and was designed to assess its safety and
tolerability. The preliminary safety report confirmed that the drug was
safe and well-tolerated.
London, 11 April 2006
ImmuPharma commences drawdown of prestigious research grants exceeding €1m
ImmuPharma PLC (LSE:IMM), the specialist pharmaceutical discovery and development company, announced today that it has started drawing down independent grants to assist with the development of its lead drug candidates. The grants which were approved in principle at the time of ImmuPharma's AIM admission in February 2006,have been awarded by ANVAR and ANR, two French state organisations that support innovative and promising R&D programmes.
London, 23 January 2006
Breakthrough drugs group ImmuPharma joins AIM
ImmuPharma plc, a drug discovery and development company focusing on the treatment of serious medical conditions such as Lupus, cancer pain and MRSA, is seeking admission to AIM.
London, 23 January 2006
Announcement from the London Stock Exchange
General Industries PLC
Proposed Reverse Takeover of ImmuPharma
Proposals for the acquisition of ImmuPharma, waiver of obligation under Rule 9 of the Takeover Code, Placing of new Shares for cash, change of directors and advisers and change of the Company's name to ImmuPharma plc
London, 15 February 2006
Announcement from the London Stock Exchange
General Industries PLC
Result of EGM and Placing
Reverse Takeover of ImmuPharma approved
At the Extraordinary General Meeting of General Industries PLC ("GI" or "the Company") held today all the resolutions were passed. These approved the acquisition of ImmuPharma PLC ("ImmuPharma"), an increase in the authorised share capital and powers of allotment; and the change of General Industries PLC's name to ImmuPharma PLC.
